Welcome to LookChem.com Sign In|Join Free

CAS

  • or
DiMethyl 5-bromo-pyridine-2,3-dicarboxylate is a pyridine derivative characterized by bromination and esterification, with the chemical formula C9H8BrNO4. It is a chemical substance primarily used in the field of organic chemistry, known for its specific chemical properties that are often utilized in various synthesis processes.

521980-82-5

Post Buying Request

521980-82-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

521980-82-5 Usage

Uses

Used in Organic Chemistry Synthesis:
DiMethyl 5-bromo-pyridine-2,3-dicarboxylate is used as a key intermediate in organic synthesis for its ability to participate in nucleophilic substitution reactions, where the bromine atom is replaced by a nucleophile. This property makes it valuable in the creation of new organic compounds and materials.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, DiMethyl 5-bromo-pyridine-2,3-dicarboxylate is used as a building block for the development of new drugs. Its unique structural features allow it to be incorporated into medicinal compounds, potentially leading to the discovery of novel therapeutic agents.
Used in Chemical Research:
DiMethyl 5-bromo-pyridine-2,3-dicarboxylate is also utilized in chemical research as a model compound to study various reaction mechanisms and to understand the behavior of pyridine derivatives under different conditions.
As an organic compound, DiMethyl 5-bromo-pyridine-2,3-dicarboxylate requires careful handling and appropriate safety measures to ensure the well-being of those working with it in laboratory and industrial settings.

Check Digit Verification of cas no

The CAS Registry Mumber 521980-82-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,2,1,9,8 and 0 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 521980-82:
(8*5)+(7*2)+(6*1)+(5*9)+(4*8)+(3*0)+(2*8)+(1*2)=155
155 % 10 = 5
So 521980-82-5 is a valid CAS Registry Number.

521980-82-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name dimethyl 5-bromopyridine-2,3-dicarboxylate

1.2 Other means of identification

Product number -
Other names dimethyl 5-bromanylpyridine-2,3-dicarboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:521980-82-5 SDS

521980-82-5Relevant articles and documents

PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES

-

Paragraph 0116; 0117; 0118, (2021/05/21)

The present invention relates to a class of TrkA inhibitors and an application thereof in the preparation of a drug for the treatment of diseases associated with TrkA. The present invention specifically discloses compounds represented by formula (I) and f

CGRP ANTAGONIST COMPOUNDS

-

Page/Page column 115, (2020/12/30)

The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

CGRP ANTAGONIST COMPOUNDS

-

Page/Page column 36; 37, (2020/12/30)

The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein A1, A2, Q, X, R1, R2 and R3 are defined herein, and their use in treating, preventing, ameliorating, control

Calcitonin gene-related peptide (CGRP) receptor antagonist treatment of migraine

Gras

, p. 869 - 879 (2020/01/21)

Migraine is ranked as the sixth cause of years lost due to disability, with around 1.04 billion migraine sufferers globally. Triptans are considered the standard for acute migraine treatment, but an important number of migraineurs do not respond to them and these drugs are contraindicated in patients with cardiovascular disease. Migraine therapy is currently undergoing tremendous development, i.e., 5-HT1F receptor agonists (ditans), anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies, and small-molecule CGRP receptor antagonists (gepants). Ubrogepant (MK-1620) is a small-molecule, potent and selective CGRP receptor antagonist. In two phase III clinical trials (ACHIEVE I and II), ubrogepant showed, at 2 hours, significant percentages of pain freedom, and absence of the most bothersome symptoms in migraine patients. In a phase III study to assess the long-term (52-week) safety and tolerability, ubrogepant displayed good tolerability, and no signs of hepatic toxicity. In March 2019, the U.S. Food and Drug Administration accepted the new drug application (NDA) for ubrogepant for the acute treatment of migraine.

TARGETING COMPOUNDS

-

Paragraph 0405, (2019/07/19)

The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Substituted ring compound and its method and use thereof

-

Paragraph 0800; 0801; 0802; 0803, (2017/08/25)

The invention provides a substituted cyclic compound as well as a use method and application thereof. The compound is a compound as shown in a formula (I) or stereoisomers, stereomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as shown in the formula (I). The invention further provides a medicament composition containing the compound. The compound and the medicament composition are capable of regulating the activity of protein kinase in a biological sample body and are used for protecting, treating or relieving proliferative diseases of patients. The formula (I) is as shown in the specification.

SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE

-

Paragraph 0284, (2014/06/24)

The present invention provides novel substituted alkynyl compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

PYRIDINE CGRP RECEPTOR ANTAGONISTS

-

Page/Page column 69; 70, (2013/12/03)

The present invention is directed to pyridine derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

ALIPHATIC SPIROLACTAM CGRP RECEPTOR ANTAGONISTS

-

Page/Page column 65; 66, (2013/12/03)

The present invention is directed to aliphatic spirolactam derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical\compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS

-

Page/Page column 18, (2012/05/21)

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 521980-82-5